Lead researcher Dixon Hu said: “Peripheral Neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief.
“There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain.
“There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group. No adverse events were reported in this study.
“Our findings demonstrate that the transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy.
“The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.”
In the UK, CBD oil is legal if it has been derived from an industrial hemp strain which contains no more than 0.2 percent THC.